Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 2 for:    inspire | Pulmonary Arterial Hypertension
Previous Study | Return to List | Next Study

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil (INSPIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03399604
Recruitment Status : Completed
First Posted : January 16, 2018
Last Update Posted : November 6, 2020
Nuventra, Inc.
Information provided by (Responsible Party):
Liquidia Technologies, Inc.

Brief Summary:
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH). A secondary objective of this study is to evaluate the comparative bioavailability of treprostinil between two formulations of inhaled therapy.

Condition or disease Intervention/treatment Phase
Primary Pulmonary Hypertension Drug: LIQ861 Inhaled Treprostinil Phase 3

Detailed Description:
One of the greatest impediments to patient treatment satisfaction with current inhaled treprostinil therapy is inconvenience. Currently, PAH patients using inhaled treprostinil may require more than 36 breaths per day using a nebulizer requiring daily set up and cleaning. The use of a discrete, hand-held dry powder inhaler to deliver treprostinil to the lungs could represent a major improvement in convenience and patient satisfaction, thereby improving the quality of life for PAH patients. Liquidia is pursuing approval of LIQ861, an inhalation dry powder formulation of treprostinil that is produced using Liquidia's PRINT® Technology (Particle Replication in Nonwetting Templates), as an alternative to current inhaled treprostinil therapy for the treatment of patients with PAH (WHO Group 1).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 121 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

The study will evaluate the long term safety and tolerability of LIQ861 in PAH patients transitioning from stable doses of inhaled treprostinil therapy, or who are taking no more than 2 approved, non-prostacylcin, oral PAH therapies.

Patients transitioning from inhaled treprostinil will be initiated at a comparable dose of LIQ861, and then titrate in 25ug incremental doses to tolerance and symptom relief. Patients adding LIQ861 to current oral therapies will start at a 25ug dose, and increase in 25ug increments on a weekly basis to tolerance and symptom relief.

A subset of the patients transitioning from inhaled treprostinil will be enrolled in a one-directional crossover to compare the bioavailability and pharmacokinetics of treprostinil as they transition to LIQ861. Serial PK sample collections will be taken on back to back days for transitioning and LIQ861 treprostinil formulations. These patients will then continue to be followed as all other patients enrolled in the study.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients
Actual Study Start Date : January 2, 2018
Actual Primary Completion Date : May 6, 2019
Actual Study Completion Date : November 25, 2019

Arm Intervention/treatment
Experimental: LIQ861 Inhaled Treprostinil

LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.

LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg to 150 μg treprostinil QID in individual patients.

Drug: LIQ861 Inhaled Treprostinil
LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
Other Names:
  • inhaled treprostinil
  • inhaled prostacyclin

Primary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events [ Time Frame: Baseline, Week 2, Month 1, Month 2 Visits, with bimonthly follow up for up to 30 months. ]
    Treatment-Emergent Adverse Events and Serious Adverse Events will be grouped by MedDRA System Organ Class, dose level, time on drug, and relationship to dose titration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • signed informed consent by patient prior to study enrollment
  • 18 years of age or older
  • If female of childbearing potential, a negative pregnancy test at the Baseline Visit and agrees to practice adequate birth control throughout the duration of the study. If the patient is postmenopausal or has documented surgical sterilization, a pregnancy test and birth control is not necessary.
  • The patient has been diagnosed with PAH belonging to the following subgroups of the updated Nice Clinical Classification Group 1 (Simonneau, Gatzoulis et al. 2013), which include:

    1. Idiopathic PAH (1.1), or
    2. Heritable PAH (1.2), or
    3. Drug and toxin induced PAH (1.3), or
    4. PAH associated with connective tissue disease (1.4.1), HIV infection (1.4.2), or congenital heart disease (1.4.4) with simple systemic-to-pulmonary shunt at least 1 year after surgical repair
  • The patient has been diagnosed with PAH and is NYHA Functional Class II - IV at Screening.

    1. has documented stable doses of approved inhaled therapy for at least 3 months prior to screening and is willing and able to transition from their prescribed dose of inhaled therapy to study drug, or
    2. has documented stable doses of no more than two approved oral therapies for at least 3 months prior to screening and is willing and able to add LIQ861 to their treatment regimen.
  • The patient can complete a baseline six-minute walk distance (6MWD) ≥ 150 m.
  • The patient has had evidence of FEV1 ≥ 60% and FEV1/FVC ratio ≥ 60% during the 6-month period prior to enrollment.

Exclusion Criteria:

  • The patient's clinical condition is such that, in the opinion of the Investigator, they are not expected to remain clinically stable for the duration of the study.
  • Patients with PH in the Updated Nice Classification Groups 2-5, or PAH Group 1 subgroups not covered by the inclusion criteria (e.g., associated with portal hypertension [1.4.3] or with schistosomiasis [1.4.5]).
  • The patient is currently taking oral prostacyclin analogues or agonists, including treprostinil and selexipag.
  • The patient has had any PAH medication (except for anticoagulants) discontinued within 14 days of Baseline.
  • The patient has had a new type of chronic therapy (including but not limited to oxygen, a different class of vasodilator, diuretic, digoxin, and digitalis) for pulmonary hypertension added within 30 days of Baseline.
  • The patient has uncontrolled systemic hypertension as evidenced by persistent systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg.
  • The patient has a history of hemodynamically significant left-sided heart disease including, but not limited to: aortic or mitral valve disease, pericardial constriction, restrictive or congestive cardiomyopathy, or coronary artery disease (CAD).
  • The patient has had an atrial septostomy.
  • The patient has any serious or life-threatening disease other than conditions associated with PAH (e.g. malignancy requiring aggressive chemotherapy, end stage renal disease, etc.).
  • The patient is taking any excluded medications listed in the Investigator's Brochure, namely inhibitors and inducers of CYP2C8
  • The patient has a hypersensitivity or allergy to any of the ingredients of LIQ861 or other clinically relevant allergies (clinical relevance per Investigator judgment).
  • The patient has had a pulmonary infarction (defined as infarction in more than one lung segment documented by V/Q scan or pulmonary angiography) within two weeks of Screening.
  • The patient has had a stroke or transient ischemic attack (TIA) within six months of Screening.
  • The patient has evidence of an active uncontrolled sepsis or systemic infection during Screening.
  • The patient is pregnant or lactating.
  • The patient has any musculoskeletal disease or any other disease that would limit ambulation.
  • The patient has participated in an investigational product or device study within the 30 days prior to Screening.
  • The patient has current evidence of drug abuse in the opinion of the Investigator.
  • The patient has severe hepatic impairment as evidenced by any history of ascites AND encephalopathy.
  • The patient has severe renal impairment (eGFR < 35).
  • The patient is taking inhaled treprostinil doses of greater than 90 μg (more than 15 breaths).

Additional Exclusion Criteria for PK Sub-Study:

  • The patient meets any of Primary Exclusion Criteria #1 - 19.
  • The patient has moderate or severe renal impairment (eGFR < 60).
  • The patient is taking inhaled treprostinil doses of greater than 72 μg (more than 12 breaths).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03399604

Show Show 38 study locations
Sponsors and Collaborators
Liquidia Technologies, Inc.
Nuventra, Inc.
Layout table for investigator information
Principal Investigator: Nicholas S Hill, MD Tufts Medical Center
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Liquidia Technologies, Inc. Identifier: NCT03399604    
Other Study ID Numbers: LTI-301
First Posted: January 16, 2018    Key Record Dates
Last Update Posted: November 6, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Liquidia Technologies, Inc.:
Pulmonary Arterial Hypertension
Idiopathic Pulmonary Arterial Hypertension
Heritable Pulmonary Arterial Hypertension
Drug Induced Pulmonary Arterial Hypertension
Toxin Induced Pulmonary Arterial Hypertension
Connective tissue disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Pulmonary Arterial Hypertension
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Antihypertensive Agents